207 related articles for article (PubMed ID: 3256508)
21. In vitro activity of ertapenem: review of recent studies.
Wexler HM
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
[TBL] [Abstract][Full Text] [Related]
22. Investigation of the antibiotic susceptibility patterns of pathogens causing nosocomial infections.
Yaman A; Tasova Y; Kibar F; Inal AS; Saltoglu N; Buyukcelik O; Kurtaran B; Dundar IH
Saudi Med J; 2004 Oct; 25(10):1403-9. PubMed ID: 15494811
[TBL] [Abstract][Full Text] [Related]
23. [Continuous surveillance of antimicrobial resistance among nosocomial gram-negative bacilli from intensive care units in China].
Chen MJ; Wang H;
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):375-81. PubMed ID: 12820912
[TBL] [Abstract][Full Text] [Related]
24. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
[TBL] [Abstract][Full Text] [Related]
25. [Analysis of predominant bacteria of burn infection and their resistance to antibiotics in recent years].
Li M; Zhang GA; Liu Y
Zhonghua Shao Shang Za Zhi; 2007 Apr; 23(2):91-3. PubMed ID: 17649879
[TBL] [Abstract][Full Text] [Related]
26. [Surveillance of antimicrobial resistance of bacteria isolated from bloodstream infections: data of the French National Observatory for Epidemiology of Bacterial Resistance to Antibiotics (ONERBA), 1998-2003].
Bertrand X; Costa Y; Pina P
Med Mal Infect; 2005 Jun; 35(6):329-34. PubMed ID: 16039819
[TBL] [Abstract][Full Text] [Related]
27. Tigecycline in vitro activity against gram-negative and gram-positive pathogens collected in Italy.
Roveta S; Marchese A; Debbia EA
Chemotherapy; 2008; 54(1):43-9. PubMed ID: 18073470
[TBL] [Abstract][Full Text] [Related]
28. [Long term care units--nest of resistant bacteria?].
Laine J; Lumio J
Duodecim; 2005; 121(15):1679-81. PubMed ID: 16211842
[No Abstract] [Full Text] [Related]
29. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents.
Sader HS; Jones RN; Stilwell MG; Dowzicky MJ; Fritsche TR
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):181-6. PubMed ID: 16105562
[TBL] [Abstract][Full Text] [Related]
30. In vitro activity of imipenem and six other beta-lactam antibiotics against aminoglycoside resistant gram-negative bacilli.
Bujdáková H; Kallová J; Lausová A; Kettner M
Microbios; 1995; 84(339):87-90. PubMed ID: 8628124
[TBL] [Abstract][Full Text] [Related]
31. Trends in antimicrobial susceptibilities among bacterial pathogens isolated from patients hospitalized in European medical centers: 6-year report of the MYSTIC Surveillance Study (1997-2002).
Turner PJ
Diagn Microbiol Infect Dis; 2005 Apr; 51(4):281-9. PubMed ID: 15808320
[TBL] [Abstract][Full Text] [Related]
32. In vitro activity of ceftobiprole against Gram-positive and Gram-negative bacteria isolated from humans and animals.
Silva N; Radhouani H; Gonçalves A; Araújo C; Rodrigues J; Igrejas G; Poeta P
J Antimicrob Chemother; 2010 Apr; 65(4):801-3. PubMed ID: 20110342
[No Abstract] [Full Text] [Related]
33. Susceptibility of clinical isolates of gram-positive and gram-negative organisms to cefatrizine.
Carlone NA; Cuffini AM; Forno Pizzoglio M; Cavallo G
Drugs Exp Clin Res; 1985; 11(7):447-51. PubMed ID: 3836867
[TBL] [Abstract][Full Text] [Related]
34. First point prevalence survey of nosocomial infections in the intensive care units of a tertiary care hospital in Albania.
Faria S; Sodano L; Dauri M; Sabato AF; Gjata A; Kito I; Llazo E; Bilaj A; Mertiraj O; Schinaia N;
J Hosp Infect; 2008 May; 69(1):95-7. PubMed ID: 18346815
[No Abstract] [Full Text] [Related]
35. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
[TBL] [Abstract][Full Text] [Related]
36. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
[TBL] [Abstract][Full Text] [Related]
37. [Susceptibility of clinical strains of gram-negative rods to selected beta-lactam antibiotics].
Rokosz A; Sawicka-Grzelak A
Med Dosw Mikrobiol; 1997; 49(3-4):191-8. PubMed ID: 9554152
[TBL] [Abstract][Full Text] [Related]
38. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
[TBL] [Abstract][Full Text] [Related]
39. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001).
Streit JM; Jones RN; Sader HS; Fritsche TR
Int J Antimicrob Agents; 2004 Aug; 24(2):111-8. PubMed ID: 15288308
[TBL] [Abstract][Full Text] [Related]
40. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
